D. D. Gummin, J. B. Mowry, and D. A. Spyker, Annual Report of the American Association of Poison Control, vol.340, 2016.

. Centers, National Poison Data System (NPDS): 34th Annual Report, Clin Toxicol (Phila), vol.55, pp.1072-1252

, Misuse of analgesics in the context of self-medication: 344 resutls of a large cross-sectional survey from the DANTE study, Abstracts of the Annual Meeting of French Society of Pharmacology and Therapeutics, and INSERM Clinical 343 Research Centers (CIC) Meeting, vol.342, pp.12-14, 2018.

M. Guerlais, Fundam Clin Pharmacol, vol.32, p.16

W. Bernal, G. Auzinger, A. Dhawan, and J. Wendon, Acute liver failure, The Lancet, vol.376, pp.190-201, 2010.

K. Hawton, H. Bergen, and S. Simkin, Long term effect of reduced pack sizes of paracetamol on poisoning 348 deaths and liver transplant activity in England and Wales: interrupted time series analyses, BMJ, vol.346, p.403, 2013.

S. E. Gulmez, D. Larrey, and G. Pageaux, Liver transplant associated with paracetamol overdose: results 350 from the seven-country SALT study, Br J Clin Pharmacol, vol.80, pp.599-606, 2015.

J. A. Vale and A. T. Proudfoot, Paracetamol (acetaminophen) poisoning, Lancet, vol.346, pp.547-552, 1995.

D. N. Bateman, Paracetamol poisoning: beyond the nomogram, Br J Clin Pharmacol, vol.80, pp.45-50, 2015.

B. H. Rumack and D. N. Bateman, Acetaminophen and acetylcysteine dose and duration: past, present and future, 2012.

, Clin Toxicol (Phila), vol.50, pp.91-98

W. M. Lee, Acetaminophen (APAP) hepatotoxicity-Isn't it time for APAP to go away?, J Hepatol, vol.67, pp.1324-1331, 2017.

R. Twycross, V. Pace, M. Mihalyo, and A. Wilcock, Acetaminophen (paracetamol), J Pain Symptom Manage, vol.46, p.747, 2013.

T. M. Caparrotta, D. J. Antoine, and J. W. Dear, Are some people at increased risk of paracetamol-induced liver injury? 359 A critical review of the literature, Eur J Clin Pharmacol, vol.74, pp.69-72, 2018.

,

F. P. Schena, Management of patients with chronic kidney disease, Intern Emerg Med, vol.6, pp.77-83, 2011.

R. C. Blantz, Acetaminophen: acute and chronic effects on renal function, Am J Kidney Dis, vol.28, pp.3-6, 1996.

D. Larrey, Is there a risk to prescribe paracetamol at therapeutic doses in patients with acute or chronic 365 liver disease?, 2006.

, Gastroenterol Clin Biol, vol.30, pp.753-755

C. Bunchorntavakul and K. R. Reddy, Acetaminophen-related hepatotoxicity, Clin Liver Dis, vol.17, p.17, 2013.

J. Kurtovic and S. M. Riordan, Paracetamol-induced hepatotoxicity at recommended dosage, J Intern Med, vol.368, pp.240-243, 2003.

L. S. Eriksson, U. Broomé, M. Kalin, and M. Lindholm, Hepatotoxicity due to repeated intake of low doses of 370 paracetamol, J Intern Med, vol.231, pp.567-570, 1992.

S. Krähenbuhl, Y. Brauchli, and O. Kummer, Acute liver failure in two patients with regular alcohol 372 consumption ingesting paracetamol at therapeutic dosage, Digestion, vol.75, pp.232-237, 2007.

P. Forget, X. Wittebole, P. Laterre, E. Arques-armoiry, D. Cabelguenne et al., Most frequent drug-related events detected by 389 pharmacists during prescription analysis in a university hospital, Rev Med Interne, vol.31, pp.804-811, 2009.

L. Zhou, S. M. Maviglia, and L. M. Mahoney, Supratherapeutic dosing of acetaminophen among hospitalized 391 patients, Arch Intern Med, vol.172, pp.1721-1728, 2012.

B. Charpiat, A. Henry, and G. Leboucher, Overdosed prescription of paracetamol (acetaminophen) in a 393 teaching hospital, Ann Pharm Fr, vol.70, pp.213-218, 2012.

F. Viguier, C. Roessle, and L. Zerhouni, , 2016.

, Ann Pharm Fr, vol.74, pp.482-488

J. Pace, V. Nave, and M. Moulis, Therapie, vol.72, pp.579-586, 2017.

H. A. Wynne, L. H. Cope, and B. Herd, The association of age and frailty with paracetamol conjugation in man, 1990.

S. J. Mitchell, S. N. Hilmer, B. P. Murnion, and S. Matthews, Hepatotoxicity of therapeutic short-course paracetamol in 401 hospital inpatients: impact of ageing and frailty, J Clin Pharm Ther, vol.36, pp.327-335, 2011.

A. Liukas, K. Kuusniemi, and R. Aantaa, Pharmacokinetics of intravenous paracetamol in elderly patients, Clin 403 Pharmacokinet, vol.50, pp.121-129, 2011.

J. Yan, S. Li, and S. Li, The role of the liver in sepsis, Int Rev Immunol, vol.33, pp.498-510, 2014.

A. K. Koehne-de-gonzalez and J. H. Lefkowitch, Heart Disease and the Liver: Pathologic Evaluation. Gastroenterol, vol.406, 2017.

, Clin North Am, vol.46, pp.421-435

, Thésaurus des interactions 408 médicamenteuses -mise à jour mars, 2018.

M. D. Leise, J. J. Poterucha, and J. A. Talwalkar, Drug-induced liver injury, Mayo Clin Proc, vol.89, pp.95-106, 2014.

K. Fisher, R. Vuppalanchi, and R. Saxena, Drug-Induced Liver Injury, Arch Pathol Lab Med, vol.139, pp.876-887, 2015.

L. C. Hawkins, J. N. Edwards, and P. I. Dargan, Impact of restricting paracetamol pack sizes on paracetamol poisoning 412 in the United Kingdom: a review of the literature, Drug Saf, vol.30, pp.465-479, 2007.

E. P. Krenzelok, The FDA Acetaminophen Advisory Committee Meeting -what is the future of acetaminophen 414 in the United States? The perspective of a committee member, Clin Toxicol (Phila), vol.47, pp.784-789, 2009.

, Federal Drug Agency (FDA) Prescription Drug Products Containing Acetaminophen: Actions to Reduce Liver Injury 416 from Unintentional Overdose. Notice Document

. Accessed, Prescription Acetaminophen Products to 419 be Limited to 325 mg Per Dosage Unit; Boxed Warning Will Highlight Potential for Severe Liver Failure, 201841843-09-10.

, Paracétamol : l'ANSM lance une consultation publique pour sensibiliser les patients et les professionnels de santé 422 au risque de toxicité pour le foie en cas de mésusage -Point d'Information -ANSM : Agence nationale de sécurité du 423 médicament et des produits de santé, 201842144-09-10.

, Résumé des caractéristiques du produit -Paracétamol Codéine EG 500 mg/ 30 mg, comprimé effervescent 429 sécable, vol.46, 2018428-09-10.

, Résumé des caractéristiques du produit -Paracétamol AHCL 1g, comprimé effervescent

, Accessed, vol.17, 201943649-01.